

# Summary Report of Consolidated Financial Results

For the nine Months Period ended December 31, 2009 (Year ending March 31, 2010)



February 10, 2010

Company name: **NIPRO CORPORATION**

TSE/OSE-1st section

Code No.8086 URL: <http://www.nipro.co.jp/>

Representative: Minoru Sano, President and Representative Director

Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division TEL: (06) 6372-2331

Filing date of quarterly reporting: February 12, 2010

Payment date of cash dividends: -

(Note: Amounts are truncated to one million yen)

## 1. Financial results for the nine months ended Dec. 31, 2009 (From April 1, 2009 to Dec. 31, 2009)

### (1) Consolidated Results of Operations (Note: The % displays show increase/decrease ratio against the same period of the previous year.)

	Net Sales		Operating Income		Ordinary Income		Net Income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
9 months ended Dec. 31, 2009	133,063	(1.1)	14,767	35.4	12,503	98.8	6,352	137.9
9 months ended Dec. 31, 2008	134,543	-	10,904	-	6,290	-	2,670	-

	Earnings per Share	Diluted Earnings per Share
9 months ended Dec. 31, 2009	100.15 Yen	- Yen
9 months ended Dec. 31, 2008	42.08	-

### (2) Consolidated Financial Position

	Total Assets	Net Assets	Equity Ratio	Net Assets per Share
	Millions of yen	Millions of yen	%	Yen
9 months ended Dec. 31, 2009	355,181	112,061	31.1	1,739.20
Year ended March 31, 2009	330,640	96,560	28.7	1,498.47

(Note) Shareholders' equity 9 months ended Dec. 31, 2009 110,307 million yen, Year ended March 31, 2009 95,049 million yen

## 2. Dividends

(Basis date)	Dividends per share				
	End of 1st Quarter	End of 2nd Quarter	End of 3rd Quarter	Year end	Year Total
Year ended March 31, 2009	yen ----	Yen 32.00	yen ----	yen 0.00	yen 32.00
Year ending March 31, 2010	----	23.50	----	----	----
Year ending March 31, 2010(Forecast)	----	----	----	25.00	48.50

(Note) Revisions to the forecast of cash dividends in the current quarter: No

## 3. Forecast of Consolidated Financial Results for the Year ending March 31, 2010 (From April 1, 2009 to March 31, 2010)

(Note: The % displays show increase/decrease ratio against the year ended March 31, 2009)

	Net Sales		Operating Income		Ordinary Income		Net Income		Earnings Per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Year ending March 31, 2010	180,000	2.3	17,400	17.8	13,000	31.4	6,050	33.5	95.35

(Note) Revisions to the forecast of consolidated financial results in the current quarter : No

#### 4. Others

(1) Changes in significant subsidiaries during the current period

(Changes in specified subsidiaries that caused a change in the scope of consolidation): No

(2) Adoption of accounting treatments simplified and unique for preparation of quarterly consolidated financial statements: Yes

(Note) For more details please see page 5. [Qualitative information, financial reports and others] 4. Other.

(3) Changes in accounting principles, procedures and disclosure for quarterly consolidated financial reports (to be stipulated in significant matters for preparation of quarterly consolidated financial reports):

[1] Changes by a newly issued accounting pronouncement: No

[2] Changes other than [1]: No

(4) Issued shares (Common stock)

[1] Number of issued shares at end of the period	9 months ended Dec. 31, 2009	Year ended March 31, 2009
(including treasury stock)	63,878,505 shares	63,878,505 shares
[2] Number of treasury stock at end of the period	9 months ended Dec. 31, 2009	Year ended March 31, 2009
	454,447 shares	447,874 shares
[3] Average number of shares during the period	9 months ended Dec. 31, 2009	9 months ended Dec. 31, 2008
	63,426,103 shares	63,451,760 shares

\*Disclaimer for appropriate use of forecasted financial results, and other special notes

The projection figures shown above are based on information that was available at the time of preparation and, therefore, actual performance and other factors may differ from these projections due to changes in circumstances and other developments. More information concerning these forecasts can be found on page 5. [Qualitative information, financial reports and others] 3. Qualitative information concerning forecast of consolidated financial results.

1. Qualitative information concerning consolidated financial results

In the first nine months of Fiscal year 2009(For the nine months ended December 31, 2009), the world economy generally remains stagnant though it is said to be gradually bottoming out as the excessive uncertainties about the financial system has decreased and there was trends toward recovery in some parts of the world. In Japan's economy, the business environment remains severe because of the worsening employment conditions and emergences of the deflationary concerns, in addition to the Dubai crisis and sharp exchange rate fluctuations, while there was pickup in production and trend toward recovery in exports.

Under such situation, we have promoted to develop advanced medical equipment, expand the pharmaceutical business, increase productive efficiency and step up the sales force, so as to improve business performance.

Therefore, the consolidated sales in the first nine months of Fiscal year 2009(For the nine months ended December 31, 2009) decreased 1.1% compared with the same period a year ago to the 133,063 million yen. As for the profit, 2.0% increase of gross profit and 11.1% decrease of selling, general and administrative expenses in the first nine months of FY2009 compared with same period a year ago resulted in operating income of 14,767 million yen, an increase of 35.4% compared with same period a year ago. Ordinary income in the first nine months of FY2009 increased 98.8% to 12,503 million yen compared with same period a year ago, thanks to the decrease of Non-operating expenses like Foreign exchange losses and Net income in the first nine months of FY2009 increased 137.9% to 6,352 million yen compared with same period a year ago.

The overviews of the results by segment in the first nine months of FY2009 are as follows.

<Medical equipment division>

As for the domestic sales, the market and business conditions became more and more server because health industry particularly in medical institution are urged to improve business efficiency under the promotion of medical system reform aimed at controlling medical expenses.

Under such circumstances, we showed consistent growth of sales and profit in each field of injection and infusion-related products such as product for the new influenza, safety-use product and enteral nutrition-related product, medical-equipment-related products like dialysis system, examine-related products like blood collection tube, blood collection needle and blood glucose meter, products related to ventricular assist device and products related to artificial heart-lungs, and vascular-related products like guiding catheters and thrombectomy catheters by means of more active sales promotion and improvement in sales efficiency.

In the international business, on the other hand, though we faced a serious challenge due to the appreciation of the yen against U.S. dollar, we have expanded our sales bases and strengthened on-site-based sales activities in expanding market in China and aggressively promoted the sales in Brazil and other Latin American countries and Europe market so that the sales shows consistent increase. By product, the businesses for artificial organ like dialyzer have grown greatly, injection and infusion-related products has increased strongly as well as diabetic devices and safety-device-related products with strong market demands have grown steadily. In addition, we have strongly advanced the inventory reduction, cost saving, so that the earnings condition has improved drastically.

As a result, net sales of this division decreased 3.6% from the same period a year ago to 82,806 million yen.

<Pharmaceutical division>

We advanced the sales of characteristics drugs and medicines, supported by the policies for the popularization of generic products under the advancement of aging society and increase of the establishments introducing DPC. As a result, we showed steady growth in sales of liquid-and-powder double-bag kits, pre-mixed-bag kits, injectable drug such as plastic-ampoules, and oral drug such as orally disintegrating tablets and extended-release tablets, as well as dialysis-related products such as kit product of substitution fluid for hemofiltration and hemodiafiltration.

We also advanced the contract manufacturing business to build up the structure which enables us to stably supply the high-quality products as the largest contract manufacturer group of pharmaceutical products in Japan, as we have started the contract-manufacturing of steroid injectable drug in new plant and won a new business in oral drug from major drug companies.

As a result, net sales of this division increased 6.2% from the same period a year ago to 43,126 million yen.

#### <Glass & Materials division>

In the field of glass for pharmaceutical purposes, the domestic demands of glass tubes for ampoule decreased due to the changes of forms of container, on the other hand, the business of glass tubes and bottles have relatively done well.

In the field of other glass & materials products, the export of glass for thermos bottles mainly to Middle East Market decreased due to the worldwide economic stagnation and stronger yen. The sales of glass for lighting purposes to automobile-related industries began to show a recovery trend to a certain extent, the sales of products related to backlight for LCD decreased significantly due to the price down and the production shift to overseas locations. As for the products other than glasses products, though the sales of daily commodity related products like Sanitary good did well, other sales remained poor due to the stagnant consumption.

As a result, net sales of this division decreased 13.7% from the same period a year ago to 6,485 million yen.

#### <Other division>

Net sales of other division, consisting mainly of sales of machine for manufacture of medical equipment and real estate rentals, increased 21.5% from the same period a year ago to 645 million yen.

## 2. Qualitative information on the consolidated financial position

### (1) Condition of the assets, liabilities and net assets

Total assets at end of this third quarterly period increased 24,540 million yen to 355,181 million yen from the end of the previous fiscal year. Current assets increased 13,915 million yen to 174,780 million yen and non-current assets increased 10,624 million yen to 180,400 million yen from end of the previous fiscal year. Current assets increased mainly due to the increase of 7,282 million yen in the Notes and accounts receivable-trade and non-current assets increased mainly due to the increase of 12,192 million yen in investment securities.

Total liabilities at end of this third quarterly period increased 9,039 million yen to 243,119 million yen from the end of the previous fiscal year. Current liabilities increased 10,565 million yen to 125,361 million yen and non-current liabilities decreased 1,525 million yen to 117,758 million yen from end of the previous fiscal year. Current liabilities increased mainly due to the increase of 14,183 million yen in short-term loans payable and non-current liabilities decreased mainly due to the decrease of 14,000 million yen in convertible bond-type bonds with subscription rights to shares.

Net assets at end of this third quarterly period increased 15,501 million yen to 112,061 million yen from the end of the previous fiscal year. Shareholders' equity increased 4,850 million yen to 104,094 million yen and valuation and translation adjustments increased 10,407 million yen to 6,212 million yen from end of the previous fiscal year. Shareholders' equity increased mainly due to the increase of 4,861 million yen in retained earnings, and valuation and translation adjustments increased mainly due to the increase of 7,866 million yen in Valuation difference on available-for-sale securities.

### (2) Condition of the consolidated Cash flows

Cash and cash equivalents (hereinafter referred to as "net cash") at the end of this third quarterly period increased 4,014 million yen to 49,366 million yen from the end of the previous fiscal year.

#### (Cash flows from operating activities)

Net cash provided by operating activities amounted to 15,681 million yen. The main accounts of inflow were income before income taxes and minority interests, 11,824 million yen, depreciation and amortization, 13,401 million yen and the main accounts of outflow were increase in notes and accounts receivable-trade, 9,286 million yen, income taxes paid, 4,091 million yen.

(Cash flows from investing activities)

Net cash used in investing activity amounted to 22,427 million yen. The main account of outflow was purchase of noncurrent assets, 22,947 million yen.

(Cash flows from financing activities)

Net cash provided by financing activities amounted to 11,254 million yen. The main accounts of inflow was increase in net increase in short-term loans payable, 12,839 million yen, commercial paper, 10,000 million yen, and proceeds from long-term loans payable, 17,777 million yen and the main accounts of outflow were repayment of long-term loans payable, 13,560 million yen and redemption of bonds 17,120 million yen.

3. Qualitative information concerning forecast of consolidated financial results

There is little sign of recovery in the world economic future, while the growing economic power of newly developing countries is expected. In Japan's economy, there is no good prospect for rapid recovery of business investment and personal consumption as well, and the business environment is expected to remain more severe for a while.

Under such circumstances, we will strive to improve production efficiency and develop sales structure continuously and aggressively develop new business field so as to improve business performance furthermore.

As for the forecast of consolidated financial results for the fiscal year 2009(April 1, 2009 through March 31, 2010), as the business performance for the FY2009 is continuing to perform as expected, there is no changes in the forecast announced on November 11, 2009.

Although we announced on February 3, 2010 to process the tender offer and the following merger and acquisition of Home Diagnostics, Inc., we expect at this moment that it would give minimal affection to the consolidated financial statements for FY2009.

4. Other

(1) Changes in significant subsidiaries during the current period (Changes in specified subsidiaries that caused a change in the scope of consolidation)

N/A

(2) Simplified accounting procedures and accounting procedures specific to quarterly consolidated financial statements

[1] Simplified accounting procedures

1) Calculation of estimated impairment for general receivables

As it was accepted that there was no significant change between the actual rate or index of bad debts accrual calculated at the end of the current quarterly consolidated accounting period and at the end of the previous consolidated accounting year, the later rate or index was utilized for estimation of impairment of general receivables.

2) Measurement for inventory

As for the inventory amount at end of the current quarterly consolidated accounting period, actual stock counting procedure was omitted and the inventory amount was calculated by the reasonable method based on the actual stock balance at end of the second quarter of this consolidated accounting year.

3) Calculation method for depreciation of noncurrent assets

The noncurrent assets depreciated in declining balance method were calculated by prorating the depreciation amount in the consolidated accounting year.

4) Deferred tax assets and liabilities

As for the judgment of collectability of deferred tax assets, the forecasted financial results and tax planning used in the end of the previous consolidated accounting year was utilized, as it was accepted that there was no significant change in the situation of accrued temporally differences from the end of the previous consolidated accounting year.

[2] Accounting procedures specific to quarterly consolidated financial statements

N/A

(3) Changes in accounting principles, procedures, and disclosure for quarterly consolidated financial statements

N/A

5. Quarterly Consolidated Financial Statements  
(1) [ Quarterly Consolidated Balance Sheets ]

(Amount: million yen)

	As of December 31, 2009	As of March 31, 2009
<b>Assets</b>		
Current assets		
Cash and deposits	53,279	49,200
Notes and accounts receivable-trade	58,229	50,947
Merchandise and finished goods	38,432	35,759
Work in process	6,046	6,410
Raw materials and supplies	9,648	8,944
Deferred tax assets	3,118	2,846
Other	6,513	7,167
Allowance for doubtful accounts	(488)	(410)
<b>Total current assets</b>	<b>174,780</b>	<b>160,865</b>
Noncurrent assets		
Property, plant and equipment		
Buildings and structures	107,173	101,361
Accumulated depreciation and impairment loss	(55,578)	(52,229)
Buildings and structures, net	51,595	49,131
Machinery, equipment and vehicles	116,423	107,843
Accumulated depreciation and impairment loss	(78,723)	(71,319)
Machinery, equipment and vehicles, net	37,699	36,524
Land	19,752	19,459
Lease Assets	1,325	93
Accumulated depreciation	(111)	(11)
Lease Assets, net	1,213	81
Construction in progress	10,601	16,847
Other	24,621	23,394
Accumulated depreciation and impairment loss	(20,194)	(18,699)
Other, net	4,427	4,694
<b>Total property, plant and equipment</b>	<b>125,289</b>	<b>126,739</b>
Intangible assets		
Goodwill	638	851
Lease Assets	65	-
Other	1,608	1,597
<b>Total intangible assets</b>	<b>2,312</b>	<b>2,448</b>
Investments and other assets		
Investment securities	49,062	36,869
Deferred tax assets	160	140
Guarantee deposits	4,132	4,229
Other	2,583	2,561
Allowance for doubtful accounts	(3,142)	(3,214)
<b>Total investments and other assets</b>	<b>52,797</b>	<b>40,587</b>
<b>Total noncurrent assets</b>	<b>180,400</b>	<b>169,775</b>
<b>Total assets</b>	<b>355,181</b>	<b>330,640</b>

(Amount: million yen)

	As of December 31, 2009	As of March 31, 2009
<b>Liabilities</b>		
Current liabilities		
Notes and accounts payable-trade	29,365	28,322
Short-term loans payable	62,362	48,179
Commercial papers	10,000	-
Current portion of bonds	3,130	6,140
Lease obligations	299	72
Accounts payable-other	3,976	4,437
Income taxes payable	3,668	2,281
Provision for bonuses	1,391	1,615
Provision for directors' bonuses	135	3
Provision for loss on business liquidation	1,954	1,954
Notes payable-facilities	3,092	14,452
Other	5,984	7,336
<b>Total current liabilities</b>	<b>125,361</b>	<b>114,795</b>
Noncurrent liabilities		
Bonds payable	38,050	35,160
Convertible bond-type bonds with subscription rights to shares	-	14,000
Long-term loans payable	67,855	65,012
Lease obligations	1,105	92
Deferred tax liabilities	6,277	913
Provision for retirement benefits	2,056	1,888
Provision for directors' retirement benefits	600	631
Provision for loss on litigation	170	170
Other	1,644	1,416
<b>Total noncurrent liabilities</b>	<b>117,758</b>	<b>119,284</b>
<b>Total liabilities</b>	<b>243,119</b>	<b>234,080</b>
Net assets		
Shareholders' equity		
Capital stock	28,663	28,663
Capital surplus	29,972	29,973
Retained earnings	46,319	41,457
Treasury stock	(860)	(849)
<b>Total shareholders' equity</b>	<b>104,094</b>	<b>99,244</b>
Valuation and translation adjustments		
Valuation difference on available-for-sale securities	12,864	4,998
Foreign currency translation adjustment	(6,652)	(9,193)
<b>Total valuation and translation adjustments</b>	<b>6,212</b>	<b>(4,195)</b>
Minority interests	1,754	1,511
<b>Total net assets</b>	<b>112,061</b>	<b>96,560</b>
<b>Total liabilities and net assets</b>	<b>355,181</b>	<b>330,640</b>

(2) [ Quarterly Consolidated Statements of Income ]  
 [ First nine months ended Dec. 31, 2009 ]

(Amount: million yen)

	FY2008 first nine months (From April 1, 2008 to Dec. 31, 2008)	FY2009 first nine months (From April 1, 2009 to Dec. 31, 2009)
Net sales	134,543	133,063
Cost of sales	95,908	93,642
Gross profit	38,635	39,421
Selling, general and administrative expenses	27,730	24,653
Operating income	10,904	14,767
Non-operating income		
Interest income	341	175
Dividends income	721	598
Other	405	534
Total non-operating income	1,468	1,308
Non-operating expenses		
Interest expenses	1,722	1,694
Depreciation	271	166
Foreign exchange losses	3,881	534
Equity in losses of affiliates	137	1,055
Other	70	121
Total non-operating expenses	6,083	3,571
Ordinary income	6,290	12,503
Extraordinary income		
Gain on sales of noncurrent assets	278	23
Settlement received	200	-
Compensation income	-	193
Surrender value of insurance	-	109
Other	161	26
Total extraordinary income	640	352
Extraordinary loss		
Loss on retirement of noncurrent assets	140	53
Impairment loss	130	-
Abnormal manufacturing cost	362	486
Loss on valuation of inventories	229	-
Corresponding loss to compensation income	-	190
Loss on product recovery	-	159
Other	316	142
Total extraordinary losses	1,180	1,031
Income before income taxes and minority interests	5,750	11,824
Income taxes-current	2,554	5,521
Income taxes-deferred	332	(295)
Total income taxes	2,886	5,225
Minority interests in income	193	246
Net income	2,670	6,352



## (3) [ Quarterly Consolidated Statements of Cash Flows ]

(Amount: million yen)

	FY2008 first nine months (From April 1, 2008 to Dec. 31, 2008)	FY2009 first nine months (From April 1, 2009 to Dec. 31, 2009)
<b>Net cash provided by (used in) operating activities</b>		
Income before income taxes and minority interests	5,750	11,824
Depreciation and amortization	13,120	13,401
Impairment loss	130	-
Amortization of goodwill	261	220
Equity in (earnings) losses of affiliates	137	1,055
Increase (decrease) in allowance for doubtful accounts	385	1
Interest and dividends income	(1,063)	(773)
Interest expenses	1,722	1,694
Foreign exchange losses (gains)	1,140	32
Decrease (increase) in notes and accounts receivable-trade	(10,451)	(9,286)
Decrease (increase) in inventories	(5,712)	(2,558)
Increase (decrease) in notes and accounts payable-trade	7,382	5,060
Decrease (increase) in other assets	(731)	230
Increase (decrease) in other liabilities	(179)	(765)
Other loss (gain)	(490)	(76)
Subtotal	11,403	20,059
Interest and dividends income received	1,011	882
Interest expenses paid	(1,618)	(1,507)
Other proceeds	730	763
Other payments	(247)	(425)
Income taxes paid	(3,403)	(4,091)
Net cash provided by (used in) operating activities	7,876	15,681
<b>Net cash provided by (used in) investing activities</b>		
Payments into time deposits	(2,267)	(1,679)
Proceeds from withdrawal of time deposits	2,001	1,604
Purchase of investment securities	(374)	(8)
Purchase of noncurrent assets	(16,171)	(22,947)
Proceeds from sales of noncurrent assets	377	55
Proceeds from governmental subsidies for investment in property and equipment	1,838	202
Net Decrease (increase) in short-term loans receivable	97	343
Collection of loans receivable	48	0
Other payments	0	-
Other proceeds	1	2
Net cash provided by (used in) investment activities	(14,447)	(22,427)

(Amount: million yen)

	FY2008 first nine months (From April 1, 2008 to Dec. 31, 2008)	FY2009 first nine months (From April 1, 2009 to Dec. 31, 2009)
Net cash provided by (used in) financing activities		
Net increase (decrease) in short-term loans payable	1,877	12,839
Increase (decrease) in commercial paper	-	10,000
Proceeds from long-term loans payable	20,250	17,777
Repayment of long-term loans payable	(10,992)	(13,560)
Proceeds from issuance of bonds	-	2,982
Redemption of bonds	(10,130)	(17,120)
Proceeds from stock issuance to minority shareholders	9	-
Decrease (increase) in treasury stock	(51)	(11)
Repayments of finance lease obligations	(30)	(152)
Cash dividends paid	(2,595)	(1,477)
Cash dividends paid for minority shareholders	-	(2)
Other payments	0	(21)
Net cash provided by (used in) financing activities	(1,662)	11,254
Effect of exchange rate change on cash and cash equivalents	(1,150)	(494)
Net increase (decrease) in cash and cash equivalents	(9,384)	4,014
Cash and cash equivalents at beginning of period	47,656	45,352
Increase in cash and cash equivalents from newly consolidated subsidiary	809	-
Cash and cash equivalents at end of period	39,082	49,366

(4) Notes related to going concern

N/A

(5) Segment information

[1] Segment information by business category

FY2008 first nine months (From April 1, 2008 to Dec. 31, 2008)

(Amount: million yen)

	Medical Equipment	Pharmaceutical	Glass & Materials	Other	Total	Eliminations /Corporate	Consolidated
Net sales							
(1)Sales to third parties	85,874	40,624	7,514	530	134,543	-	134,543
(2)Inter-segment sales and transfers	-	0	2,529	56	2,586	(2,586)	-
Total	85,874	40,624	10,044	586	137,130	(2,586)	134,543
Operating income(loss)	11,418	3,573	1,370	8	16,371	(5,466)	10,904

FY2009 first nine months (From April 1, 2009 to Dec. 31, 2009)

(Amount: million yen)

	Medical Equipment	Pharmaceutical	Glass & Materials	Other	Total	Eliminations /Corporate	Consolidated
Net sales							
(1)Sales to third parties	82,806	43,126	6,485	645	133,063	-	133,063
(2)Inter-segment sales and transfers	-	0	3,079	70	3,149	(3,149)	-
Total	82,806	43,126	9,564	715	136,213	(3,149)	133,063
Operating income(loss)	14,045	4,037	1,417	70	19,571	(4,803)	14,767

(Notes) 1. Classification of business categories and main products and commodities in each business category  
Business categories are classified based on the proximity in terms of purposes and manners of usage of the products in the market.

Main products belonging to each business categories are as follows:

Business category	Main products and commodities
Medical Equipment	Dialyzers, blood tubing sets, injection needles, syringes, and infusion sets, etc.
Pharmaceutical	Half-type and full-type kits, double-bag kits, pre-filled syringes, dialysate solution, and circulatory drugs, etc.
Glass & Materials	Glass for pharmaceutical containers, glass for thermos bottles, glass for lighting purposes, stoppers for plastic containers and rubber stoppers, etc.
Other	Machinery for manufacture of medical equipment and real estate rental income, etc.

[2] Segment information by geographical area

FY2008 first nine months (From April 1, 2008 to Dec. 31, 2008)

(Amount: million yen)

	Japan	America	Europe	Asia	Total	Eliminations /Corporate	Consolidated
Net sales							
(1)Sales to third parties	103,585	15,879	9,344	5,734	134,543	-	134,543
(2)Inter-segment sales and transfers	24,051	742	1	10,858	35,653	(35,653)	-
Total	127,636	16,621	9,345	16,593	170,197	(35,653)	134,543
Operating income(loss)	16,134	(741)	3	910	16,307	(5,402)	10,904

FY2009 first nine months (From April 1, 2009 to Dec. 31, 2009)

(Amount: million yen)

	Japan	America	Europe	Asia	Total	Eliminations /Corporate	Consolidated
Net sales							
(1)Sales to third parties	104,723	13,209	9,613	5,517	133,063	-	133,063
(2)Inter-segment sales and transfers	22,356	488	3	11,439	34,287	(34,287)	-
Total	127,079	13,697	9,616	16,956	167,351	(34,287)	133,063
Operating income(loss)	18,301	(49)	78	1,652	19,982	(5,214)	14,767

(Notes)

1. Classification of countries or areas is based on geographical proximity.
2. The major countries included in each geographical area are as follows:
  - America..... The United States of America and Brazil
  - Europe..... Belgium
  - Asia..... China, Thailand and Singapore

[3] Overseas Sales

FY2008 first nine months (From April 1, 2008 to Dec. 31, 2008) (Amount: million yen)

	America	Europe	Asia	Total
1. Overseas sales	25,326	14,995	7,921	48,244
2. Consolidated net sales				134,543
3. Percentage of overseas sales to consolidated net sales (%)	18.8%	11.2%	5.9%	35.9%

FY2009 first nine months (From April 1, 2009 to Dec. 31, 2009) (Amount: million yen)

	America	Europe	Asia	Total
1. Overseas sales	21,121	15,226	7,744	44,092
2. Consolidated net sales				133,063
3. Percentage of overseas sales to consolidated net sales (%)	15.9%	11.4%	5.8%	33.1%

- (Notes) 1. Overseas sales represent those of the Company and the consolidated subsidiaries to countries and areas outside of Japan  
 2. Classification of countries or areas is based on geographical proximity.  
 3. The major countries included in each geographical area are as follows:  
     America..... The United States of America, Canada and Brazil  
     Europe..... Belgium, Denmark and Germany  
     Asia..... China, India, Indonesia, Taiwan and Thailand

(6) Notes to Statements of Shareholders' Equity, if having significant variation.

N/A